UNH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
UnitedHealth Group Inc (UNH) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company operates in a resilient sector and has positive catalysts such as Medicare rate increases, its recent financial performance shows significant declines in net income and EPS. Additionally, technical indicators suggest the stock is overbought, and there are no strong proprietary trading signals today. The upcoming earnings report on April 21 could provide more clarity, but for now, holding off on a purchase is recommended.
The stock is currently trading in the pre-market at $318.93, up 0.80%. The RSI of 83.402 indicates the stock is overbought, and the MACD histogram is positive at 4.544, suggesting bullish momentum but contracting. Moving averages are converging, and the stock is near its resistance level of $316.794, with the next resistance at $328.143. Support levels are at $280.053 and $268.704. Short-term trends suggest a 50% chance of minor gains in the next day but significant downside risks in the next week (-4.88%) and month (-27.51%).
Medicare Advantage rate increases finalized at 2.5%, higher than expected, providing long-term visibility and potential margin improvement.
Analysts have maintained positive ratings with price targets ranging from $300 to $411, indicating potential upside.
The healthcare sector remains resilient with rising healthcare spending and an aging population driving demand.
Significant decline in Q4 2025 financial performance, with net income down 99.82% YoY and EPS down 99.83% YoY.
The stock is overbought based on RSI, and technical trends suggest potential downside in the short term.
No recent insider or hedge fund activity to signal strong confidence.
Upcoming earnings report on April 21 adds uncertainty.
In Q4 2025, UnitedHealth reported revenue growth of 13.46% YoY to $113.575 billion. However, net income dropped sharply by 99.82% YoY to $10 million, and EPS fell 99.83% YoY to $0.01. Gross margin remained flat at 0%. The financial performance indicates significant challenges in profitability despite revenue growth.
Analysts generally maintain positive ratings on UNH, with recent upgrades and price targets ranging from $300 to $411. Morgan Stanley named it a Top Pick with a $375 target, citing clean quarters ahead. However, some firms have lowered price targets due to weaker-than-expected Q4 results and guidance. The overall sentiment remains cautiously optimistic.
